robinson calcagnie robinson shapiro davis inc

Future of Type 2 Diabetes Drugs Threatened

According to The New York Times, an animal study requested by Merck for its type 2 diabetes drug, Januvia, revealed worrisome changes in the pancreases of rats, leading to follow-up studies which now threaten the future of the lucrative diabetes drug, as well as all other drugs in its class.

Impact of the Physician Payment Sunshine Act on State Regulations: Adoption of General Compliance Programs, Data Mining, DOJ Compliance

In addition to the gift ban laws discussed in our last series post, certain states require drug companies to adopt general compliance programs. Both Connecticut and California require drug companies to adopt such programs in accordance with the Office of Inspector General’s “Compliance Program Guidance for Pharmaceutical Manufacturers.” There are several elements in the guidance…

read more